Can Editas Medicine Stock Bounce Back After A 13% Drop In 5 Days ?

Editas Medicine, a biotechnology company focused on developing treatments using gene editing technology, has plunged by 13% over the last 5 trading days, after the company stated its plans to issue 3.5 million shares at $66 per share. The selling pressure can be attributed to the fact that the...